Curasight has announced a rights issue aiming to raise approximately 100 million DKK. The company has already secured approximately DKK 65 million in financing, comprising around DKK 47 million through pre-subscriptions and guarantee commitments in the rights issue. In addition, Curasight has secured and renegotiated approximately DKK 18 million in loan facilities. Nearly half of the secured capital in the rights issue is attributable to support from Curium International Trading B.V and Pentwater Capital Management Europe LLP. Proceeds will be used to secure clinical development towards key milestones, including the completion of phase II for the company's diagnostic platform uTRACE in prostate cancer and phase I for the therapeutic platform uTREAT in aggressive brain cancer  - glioblastoma. We spoke with CEO Ulrich Krasilnikoff to learn more.